Opdivo replaces Nivolumab BMS for treatment of lung cancer

Opdivo (nivolumab) is now indicated in the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy, in addition to its original indication in melanoma.

Nivolumab was originally launched for the treatment of NSCLC as Nivolumab BMS, but the manufacturer has now reconciled both indications under the Opdivo brand name. The two brands contain identical presentations of nivolumab and the same dosage regimen is used in both types of cancer.

The discontinuation of Nivolumab BMS will have no impact on patients with lung cancer already being prescribed nivolumab, other than a change in the brand name of their treatment.